Aller au contenu

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Nom du journal : The Lancet Oncology

Année : 2020

Volume : 21

Page de départ : 1353

Page de fin : 1365

Auteurs: Xu L, Piha-Paul SA, Shapira-Frommer R, Chung HC, Shah M, Delord JP, Italiano A, Marabelle A, Fakih M, Lopez J, Nakagawa K, Kindler HL, Lopez-Martin JA, Miller WH, Kao S, McWilliams RR, Fabrizio DA, Aurora-Garg D, Jin F, Norwood K, Bang YJ,